| 2.79 -0.1 (-3.46%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.35 |
1-year : | 5.17 |
| Resists | First : | 3.73 |
Second : | 4.42 |
| Pivot price | 2.91 |
|||
| Supports | First : | 2.59 | Second : | 2.16 |
| MAs | MA(5) : | 3.02 |
MA(20) : | 3.14 |
| MA(100) : | 5.25 |
MA(250) : | 5.35 |
|
| MACD | MACD : | -0.5  |
Signal : | -0.6 |
| %K %D | K(14,3) : | 27.5 |
D(3) : | 31.5 |
| RSI | RSI(14): 34.4 |
|||
| 52-week | High : | 15 | Low : | 2.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DWTX ] has closed above bottom band by 29.6%. Bollinger Bands are 67.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.05 - 3.06 | 3.06 - 3.08 |
| Low: | 2.72 - 2.74 | 2.74 - 2.76 |
| Close: | 2.76 - 2.79 | 2.79 - 2.82 |
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Tue, 20 Jan 2026
Dogwood Therapeutics outlines 2026 plans for pain pipeline - The Globe and Mail
Tue, 13 Jan 2026
Dogwood Therapeutics Signs Multiple Material Agreements - TradingView
Mon, 12 Jan 2026
New funding backs a non-opioid drug for chemotherapy nerve pain - Stock Titan
Mon, 12 Jan 2026
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development - Yahoo Finance
Wed, 24 Dec 2025
What's Driving the Market Sentiment Around Dogwood Therapeutics Inc? - Dogwood Therapeutics (NASDAQ:DWTX) - Benzinga
Mon, 22 Dec 2025
Dogwood Therapeutics Announces Positive Interim Phase 2b - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 84.2 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 82 (K) |
| Shares Short P.Month | 62 (K) |
| EPS | -25.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -14.43 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.1 % |
| Return on Equity (ttm) | -931 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.11 |
| PEG Ratio | 0 |
| Price to Book value | -0.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|